February 1, 2022 01:39 PM EST
R&D

Bak­er's dozen: Pfiz­er joins 12 peers in re­strict­ing sales of dis­count­ed drugs un­der a fed­er­al pro­gram

Zachary Brennan

Senior Editor

Be­gin­ning in March, Pfiz­er will be­come the 13th phar­ma com­pa­ny to re­strict sales of its drugs through a fed­er­al pro­gram that of­fers steep dis­counts for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Biotech VC firm out­lines plans for $100M fund

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Reg­u­la­to­ry RNA start­up CAMP4 files for IPO as more biotechs line up list­ings

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times